Citadel Advisors
RPRX icon

Citadel Advisors’s Royalty Pharma RPRX Stock Holding History

Citadel Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$460K Sell
8,200
-32,900
-80% -$1.71M ﹤0.01% 10067
2026
Q1 		$1.97M Buy
41,100
+3,800
+10% +$166K ﹤0.01% 6086
2025
Q4 		$1.44M Buy
37,300
+19,000
+104% +$725K ﹤0.01% 6602
2025
Q3 		$646K Sell
18,300
-51,100
-74% -$1.85M ﹤0.01% 8520
2025
Q2 		$2.5M Buy
69,400
+2,800
+4% +$92.8K ﹤0.01% 5299
2025
Q1 		$2.07M Buy
66,600
+15,600
+31% +$494K ﹤0.01% 5470
2024
Q4 		$1.3M Buy
51,000
+37,700
+283% +$1,000K ﹤0.01% 6505
2024
Q3 		$376K Sell
13,300
-14,600
-52% -$404K ﹤0.01% 8835
2024
Q2 		$736K Sell
27,900
-61,500
-69% -$1.7M ﹤0.01% 7254
2024
Q1 		$2.72M Sell
89,400
-28,900
-24% -$852K ﹤0.01% 4961
2023
Q4 		$3.32M Buy
118,300
+31,200
+36% +$857K ﹤0.01% 4481
2023
Q3 		$2.36M Buy
87,100
+29,300
+51% +$870K ﹤0.01% 4914
2023
Q2 		$1.78M Buy
57,800
+3,700
+7% +$125K ﹤0.01% 5354
2023
Q1 		$1.95M Buy
54,100
+7,800
+17% +$289K ﹤0.01% 5432
2022
Q4 		$1.83M Sell
46,300
-19,600
-30% -$818K ﹤0.01% 5644
2022
Q3 		$2.65M Buy
65,900
+44,400
+207% +$1.9M ﹤0.01% 5060
2022
Q2 		$904K Sell
21,500
-7,200
-25% -$295K ﹤0.01% 7248
2022
Q1 		$1.12M Buy
28,700
+12,800
+81% +$503K ﹤0.01% 7447
2021
Q4 		$634K Buy
15,900
+3,800
+31% +$148K ﹤0.01% 9084
2021
Q3 		$437K Sell
12,100
-44,400
-79% -$1.73M ﹤0.01% 10209
2021
Q2 		$2.32M Sell
56,500
-39,400
-41% -$1.68M ﹤0.01% 6226
2021
Q1 		$4.18M Sell
95,900
-97,600
-50% -$4.63M ﹤0.01% 4668
2020
Q4 		$9.69M Buy
193,500
+171,600
+784% +$7.28M ﹤0.01% 2671
2020
Q3 		$921K Buy
+21,900
New +$940K ﹤0.01% 6188

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's RPRX Position: Q2 2026 in Review

Citadel Advisors reduced its Royalty Pharma (RPRX) stake by 49% in Q2 2026, selling an estimated $69M and leaving 1,354,640 shares worth $76M. The position accounts for 0.01% of the portfolio, ranked #1188.

Citadel Advisors first reported a position in RPRX in Q2 2020 and has held it in 23 quarters since. The position peaked at $204M in Q4 2025. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Citadel Advisors held 1,354,640 shares of Royalty Pharma worth $76M as of Q2 2026.
  • Citadel Advisors sold 1,326,429 Royalty Pharma shares in Q2 2026, an estimated $69M.
  • Royalty Pharma made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #1188 holding.
  • Citadel Advisors first reported a position in Royalty Pharma in Q2 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Royalty Pharma position peaked at $204M in Q4 2025.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.